ÀÌÇü·¡ ¸íÀÇ

Àü¸³¼±¾Ï ¡¤ Àü¸³¼± Áúȯ ÇØ°á, ÃֽŠ·Îº¿ ¡¤ º¹°­°æ ¼ö¼ú ±ÇÀ§ÀÚ

ÀÌÇü·¡ ¸íÀÇ

  • ¼Ò ¼Ó
    °­µ¿°æÈñ´ëÇб³º´¿ø ºñ´¢±â°ú
  • Àü¹®ºÐ¾ß
    Àü¸³¼±ºñ´ëÁõ, Àü¸³¼±¾Ï, ºñ´¢±âÁ¾¾ç, ³²¼º°»³â±â, º¹°­°æ¼ö¼ú, ·Îº¿¼ö¼ú

Àü¸³¼±ºñ´ëÁõ, Àü¸³¼±¾Ï, ¿©¼º ¿ä½Ç±Ý Ä¡·á¿¡ ÀÖ¾î dzºÎÇÑ ÀÓ»ó°æÇè°ú ³ëÇϿ츦 °¡Áø ´ë°¡´Ù.
Áø·á Àü¹®ºÐ¾ß´Â ºñ´¢±â ÁúȯÀ¸·Î Àü¸³¼±¾ÏÀ» ºñ·ÔÇÑ ºñ´¢±âÁ¾¾ç, Àü¸³¼±ºñ´ëÁõ, ³²¼º°»³â±â µîÀ» ´Ù·é´Ù. Àü¸³¼±¾ÏÀÇ °æ¿ì ȯÀÚÀÇ »óÅ¿¡ ÃÖÀûÈ­µÈ Ä¡·á¹ýÀ» ¼±ÅÃÇϰí Á¾¾ç Àç¹ß ¹× Ä¡·á °ü·Ã ÇÕº´ÁõÀ» ÃÖ¼ÒÈ­ÇÏ´Â ¼ö¼ú¹ýÀ» Ãß±¸ÇÑ´Ù. ƯÈ÷ ºñ´¢±âÁ¾¾ç ÃÖ¼Òħ½À¼ö¼úÀÎ º¹°­°æ ¼ö¼ú°ú ·Îº¿¼ö¼ú¿¡ ÀÖ¾î ÃÖ»óÀÇ Ä¡·á°á°ú¸¦ ³ªÅ¸³»´Â µî ¸í¼ºÀÌ ³ô´Ù. Ȱ¹ßÇÑ ¿¬±¸ Ȱµ¿À¸·Î ÃÖ±Ù 10³â µ¿¾È ±¹³»¿Ü À¯¸í ÇмúÁö¿¡ 100¿© ÆíÀÇ ³í¹®À» º¸°íÇÏ¿© ´Ù¼öÀÇ Çмú»óÀ» ¼ö»óÇß´Ù. °­µ¿°æÈñ´ëÇб³º´¿ø¿¡¼­ º´¿øÀå, ±âȹÁ¶Á¤½ÇÀå, ±¹Á¦±³·ù½ÇÀå, ±³·ùÇù·Âº»ºÎÀå, ºñ´¢±â°úÀåÀ» ¿ªÀÓÇßÀ¸¸ç, ´ëÇѺñ´¢±â°úÇÐȸ¡¤´ëÇÑÀü¸³¼±ÇÐȸ µî ÇÐȸ¿¡¼­ Çмú ¹× ±¹¹Î°Ç°­ È«º¸ Ȱµ¿À» ÁøÇàÇß´Ù. ¿­½ÉÈ÷ ÀÏÇÑ ÈÄÀÇ »ç»ö°ú ¹Ì½Ä, ¹ÌÁÖ, ¿©ÇàÀ» Áñ±â¸ç, Æò¼Ò °É¾î ´Ù´Ï±â°¡ °Ç°­ÀÇ ºñ°áÀÌ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • 2007~ 2010 °æÈñ´ëÇб³ °æ¿µÇÐ ¼®»ç
  • 1993~ 1996 °æÈñ´ëÇб³ Àǰú´ëÇпø ¹Ú»ç ÇÐÀ§(ºñ´¢±â°úÇÐ Àü°ø)
  • 1991~ 1993 °æÈñ´ëÇб³ Àǰú´ëÇпø ¼®»ç ÇÐÀ§(ºñ´¢±â°úÇÐ Àü°ø)
  • 1981~ 1987 °æÈñ´ëÇб³ ÀÇÇаú Á¹¾÷

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) °­µ¿°æÈñ´ëÇб³º´¿ø ºñ´¢±â°ú ±³¼ö
  • 2018~ 2022 °­µ¿°æÈñ´ëÇб³ÀǴ뺴¿ø º´¿øÀå
  • 2014~ 2018 °­µ¿°æÈñ´ëÇб³º´¿ø ±âȹÁ¶Á¤½ÇÀå
  • 2006~ 2015 °­µ¿°æÈñ´ëÇб³º´¿ø ºñ´¢±â°ú °úÀå ¿ªÀÓ
  • 2011~ 2012 °­µ¿°æÈñ´ëÇб³º´¿ø °æÈñ±¹Á¦Áø·á¼Ò ¼ÒÀå
  • 2011~ 2012 °­µ¿°æÈñ´ëÇб³º´¿ø ±¹Á¦±³·ù½ÇÀå
  • 2009~ 2011 °­µ¿°æÈñ´ëÇб³º´¿ø ±³·ùÇù·Âº»ºÎÀå
  • 2004~ 2006 ÃæºÏ´ëÇб³º´¿ø ±âȹȫº¸ÆÀÀå
  • 2002~ 2006 ÃæºÏ´ëÇб³º´¿ø ºñ´¢±â°ú ÁÖÀÓ±³¼ö, °úÀå
  • 2000~ 2002 ¹Ì±¹ ¹Ì½Ã°£´ëÇб³ ºÎ¼Óº´¿ø ÀÓ»ó±³¼ö(Àü¸³¼± ¹× ¿ä½Ç±Ý)
  • 2000~ 2002 ¹Ì±¹ ¹Ì½Ã°£´ëÇб³ ¾Ï¼¾ÅÍ ±³È¯±³¼ö(Àü¸³¼±¾Ï)
  • 1998~ 2003 ÃæºÏ´ëÇб³º´¿ø Á¶±³¼ö
  • 1996~ 1996 »ï¼º¼­¿ïº´¿ø ºñ´¢±â°ú ÀüÀÓÀÇ

ÇÐȸȰµ¿

Academic activities
  • 1987 ~ ÇöÀç´ëÇÑÀÇÇÐȸ Á¤È¸¿ø
  • 1995 ~ ÇöÀç´ëÇѺñ´¢±â°úÇÐȸ Á¤È¸¿ø
  • 1999 ~ ÇöÀç¹Ì±¹ºñ´¢±â°úÇÐȸ ȸ¿ø
  • 1999 ~ ÇöÀçÀ¯·´ºñ´¢±â°úÇÐȸ Á¤È¸¿ø
Àü¸³¼± ºñ´ëÁõ ±³°ú¼­
´ëÇ¥¼­Àû

Àü¸³¼± ºñ´ëÁõ ±³°ú¼­

  • ÀúÀÚ(±Û)
  • ÃâÆÇ»çÀÏÁ¶°¢
  • ¹ßÇàÀÏ2005³â
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 3°Ç
Á¦ ¸ñ ¾Ë±â ½±°Ô ¾´ Àü¸³¼± Áúȯ
ÃâÆÇ»ç ÀÇÇй®È­»ç ¹ßÇàÀÏ 2006³â
Á¦ ¸ñ ¹æ±¤¾Ï Áø·áÁöħ
ÃâÆÇ»ç ÀÇÇй®È­»ç ¹ßÇàÀÏ 2005³â
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Risk Factors for Sepsis after Retrograde Intrarenal Surgery: Single Center Experience
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Urogenital Tract Infection
Á¦ ¸ñ Aggressive Paraganglioma of the Urinary Bladder with Local Recurrence and Pelvic Metastasis
¹ßÇ¥³âµµ 2020 ¹ßÇ¥Áö PATHOLOGY & ONCOLOGY RESEARCH
Á¦ ¸ñ Practice pattern of non-muscle invasive bladder cancer in Japan, Korea and Taiwan: A Web-based survey
¹ßÇ¥³âµµ 2019 ¹ßÇ¥Áö International Journal of Urology
Á¦ ¸ñ Is Double J Stenting or Percutaneous Nephrostomy More Suitable for Maximizing the Clinical Effects of Temporary Urinary Diversion for Acute Pyelonephritis with a Complicated Ureteral Stone?
¹ßÇ¥³âµµ 2019 ¹ßÇ¥Áö Urogenital Tract Infection.
Á¦ ¸ñ Blood culture for complicated acute pyelonephritis with ureteral stone: are they unnecessary?
¹ßÇ¥³âµµ 2018 ¹ßÇ¥Áö Infectious Diseases.
Á¦ ¸ñ Prognostic Significance of Immunohistochemical MSH2 Expression in Prostate Cancer
¹ßÇ¥³âµµ 2018 ¹ßÇ¥Áö ´ëÇѺñ´¢±âÁ¾¾çÇмúÁö
Á¦ ¸ñ Heterogeneous oncologic outcomes according to surgical pathology in high-risk prostate cancer: implications for better risk stratification and preoperative prediction of oncologic outcomes
¹ßÇ¥³âµµ 2017 ¹ßÇ¥Áö JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

Àü¸³¼± ¾ÏÀÇ Á¶±âÁø´Ü ¹× ÀûÁ¤Ä¡·á¸¦ ÅëÇØ »ý¸íÀÇ ¿¬ÀåÀÌ ÁÖ °ü½É»ç·Î ±¹³» ÃÖÃÊ·Î Àü¸³¼±¾Ï ÀÇ½É È¯ÀÚ »ý°ËÈÄ ´çÀÏ·Î °á°ú¸¦ µµÃâÇÏ¿© ȯÀÚÀÇ ½É¸®Àû ¾ÈÁ¤°ú ºü¸¥ ÈÄ¼Ó Ä¡·áÀÇ ¹ßÆÇÀ» ¸¶·ÃÇÏ´Â ½Ã½ºÅÛ ¸¶·Ã

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

ȯÀÚÀÔÀå¿¡¼­ ÁúȯÀ» ¹Ù¶óº¸¸ç ÀÇ»ç¿Í ȯÀÚ°£ÀÇ ÃæºÐÇÑ °ø°¨´ë ¹× °¨Á¤ÀÇ ¼ÒÅëÀ» ÅëÇØ ½Å·Ú¸¦ ¹ÙÅÁÀ¸·Î Á¾¾çÀ» À̰ܳª°¡´Â ÀÇ»ç, ȯÀÚÀÇ ¿øÆÀ ±¸¼º

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

¸¹Àº ºñ´¢±âÁúȯÀÌ ³ëÈ­¿Í ´õºÒ¾î ³ªÅ¸³²À¸·Î ±ä È£ÈíÀ¸·Î Æò¾ÈÇÑ Åµµ·Î Áúº´ ¹× ³ëÈ­¿Í ´ëÈ­ÇÑ´Ù´Â »ý°¢À¸·Î ¸ðµç ºñ´¢±âÁúȯÀ» ´ëÇϸé ÈξÀ ÁÁÀº Á¤½ÅÀû À°Ã¼Àû °á°ú·Î µ¹¾Æ¿É´Ï´Ù.

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°­µ¿°æÈñ´ëÇб³º´¿ø

Á¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1577-5800
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°­µ¿°æÈñ´ëÇб³º´¿øÀº Àǰú, ÇÑÀǰú, Ä¡°ú´ëÇÐÀ» ¸ðµÎ º¸À¯ÇÑ º´¿øÀ¸·Î, 3°³ ´ëÇк´¿øÀÇ ¼öÁØ ³ôÀº ÀÇ·á¼­ºñ½º¸¦ ÇÑ ¹ø¿¡ ¹ÞÀ» ¼ö ÀÖ´Ù. ¿¬¸éÀû 24,000¿© Æò º»°ü Áö»ó 14Ãþ, º°°ü Áö»ó 4ÃþÀÇ 800º´»óÀ» °®Ãè´Ù. ³úÁúȯ¡¤°üÀý¡¤Ã´Ãß µî Áúȯ Áß½ÉÀ¸·Î ƯȭµÈ ÇùÁø ÀÇ·á
¼­ºñ½º¸¦ Á¦°øÇÏ´Â ÀÇ¡¤ÇÑ ÇùÁø¼¾ÅÍ, ȯÀÚ ¼¼°è ÃÖ°í ¼öÁØÀÇ Áø·á½Ã½ºÅÛÀ» °®Ãá Àǰú
´ëÇк´¿ø, ÇÑÀÇÇÐÀ» ¼±µµÇÏ´Â ÇÑ¹æ ºê·£µåÆÄÀ§ 1À§ ÇÑÀǰú´ëÇк´¿ø¿Í Àü¹®¼º°ú ÆíÀǼºÀ» °®Ãá ȯÀÚ¸¸Á· º´¿øÀÎ Ä¡°ú´ëÇк´¿øÀÌ ÃÖ»óÀÇ ÀÇ·á¼­ºñ½º¸¦ Á¦°øÇϰí ÀÖ´Ù.

°­µ¿°æÈñ´ëÇб³º´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã °­µ¿±¸ µ¿³²·Î 892

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä